Company Profile · Healthcare

WuXi AppTec Co Ltd H

2359 · HK
Exchange
HK
Country
Hong Kong
Employees
33,834
Current Price
HK$128.7
Live · Jun 18, 2026
Fair Buy
≤ HK$80
Margin-of-safety entry
Baillie Growth Score
46/100
Weak
Intrinsic Value · Three-Tier Range Current price HK$128.7 Live · Within the fair intrinsic-value range

Composite valuation range · conservative HK$92–HK$110 / fair HK$118–HK$158 / optimistic HK$180–HK$219. At HK$128.7, Within the fair intrinsic-value range.

At publication HK$125.6 (Jun 5, 2026)

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manufacturing organization (CDRMO) services for new drug development from discovery to commercial covering various categories for various synthetic molecular modalities, including small molecules, oligonucleotides, peptides, and complex conjugates; and biology services and solutions which support stand-alone and integrated projects from target discovery to candidate selection and into the clinic. The company also provides laboratory testing services, such as toxicology, DMPK, and bioanalytical services; clinical contract research organization services, including Phase I to Phase IV clinical development services, and bioequivalence for products including pharmaceuticals and biologics; and site management organization, patient recruitment, site start-up, and academic research organization. In addition, it offers services for biology; CDRMO platform for small molecules, oligonucleotides, and peptides; drug research and development testing; and clinical research services. WuXi AppTec Co., Ltd. was founded in 2000 and is headquartered in Shanghai, the People's Republic of China.

Market capHK$384.01B
Revenue (TTM)HK$46.2B
EBITDAHK$21.84B
Profit margin43.57%
ROE25.7%
P/E (TTM)16.11
Forward P/E16.69
EPSHK$6.97
Dividend yield1.57%
52-week rangeHK$70.72 – HK$146.08

Data from EODHD, shown in the reporting currency; for reference only, not investment advice.

History

Coming soonThis section is being filled in — check back soon.

Industry position

Coming soonThis section is being filled in — check back soon.